• NuCana annual report for year ended Dec. 31, 2025 highlighted pipeline focus shifting toward NUC-7738, with Phase 2 NuTide:701 expansion in metastatic melanoma started in June 2025 and final expansion data targeted for 2026.
• Regulatory planning moved up for NUC-7738, with FDA guidance on potential registrational pathway in melanoma targeted for 2026.
• NUC-3373 program shifted into evaluation mode, with management reviewing combinations and indications following NuTide:303 modular study signals in advanced solid tumors; development plan expected in 2026.
• Funding strategy centered on equity issuance, including May 2025 registered direct offering raising GBP 9.6 million gross and expanded ATM activity; cash runway projected into 2029 under current plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.